Fig. 1From: Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure(Top) Calibration plots for the observed and predicted risk according to clinical markers, for A composite kidney (defined as the composite of sustained 40% decline of eGFR, end-stage kidney disease with eGFR < 15 mL/min/1.73 m², or need for dialysis or kidney transplantation, or kidney death); and B composite heart failure outcome in the CANVAS trial. (Bottom) Calibration plots for the observed and predicted risk according to clinical and novel biomarkers, for the C composite kidney and D composite heart failure outcome in the CANVAS trialBack to article page